Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options: results from a phase I study
Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 2019
|
| In: |
Haematologica
Year: 2019, Volume: 104, Issue: 2, Pages: e63-e64 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2018.199794 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.3324/haematol.2018.199794 Verlag, Volltext: http://www.haematologica.org/content/104/2/e63 
|
| Author Notes: | Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1588230805 | ||
| 003 | DE-627 | ||
| 005 | 20220815114710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190228s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2018.199794 |2 doi | |
| 035 | |a (DE-627)1588230805 | ||
| 035 | |a (DE-576)518230805 | ||
| 035 | |a (DE-599)BSZ518230805 | ||
| 035 | |a (OCoLC)1341040796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hütter-Krönke, Marie-Luise |d 1979- |e VerfasserIn |0 (DE-588)141375086 |0 (DE-627)703962760 |0 (DE-576)323320716 |4 aut | |
| 245 | 1 | 0 | |a Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options |b results from a phase I study |c Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk |
| 264 | 1 | |c February 2019 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.02.2019 | ||
| 520 | |a Lenalidomide is an immunomodulatory drug approved for multiple myeloma, relapsed mantle cell lymphoma and myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Based on the high rate of hematologic improvement and cytogenetic responses seen in del(5q) MDS, several trials have been | ||
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 104(2019), 2, Seite e63-e64 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options results from a phase I study |
| 773 | 1 | 8 | |g volume:104 |g year:2019 |g number:2 |g pages:e63-e64 |g extent:2 |a Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options results from a phase I study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2018.199794 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.haematologica.org/content/104/2/e63 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190228 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 7 |y j | ||
| 999 | |a KXP-PPN1588230805 |e 3057020321 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"results from a phase I study","title":"Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options","title_sort":"Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"2 S."}],"id":{"doi":["10.3324/haematol.2018.199794"],"eki":["1588230805"]},"relHost":[{"pubHistory":["99.2014 -"],"note":["Gesehen am 27.05.2022"],"language":["eng"],"part":{"year":"2019","volume":"104","text":"104(2019), 2, Seite e63-e64","issue":"2","pages":"e63-e64","extent":"2"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"disp":"Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options results from a phase I studyHaematologica","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"814204899","origin":[{"dateIssuedKey":"2014","publisherPlace":"Pavia","publisher":"Ferrata Storti Foundation","dateIssuedDisp":"2014-"}],"title":[{"title_sort":"Haematologica","title":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2805244-4"],"issn":["1592-8721"],"eki":["814204899"]}}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"February 2019"}],"language":["eng"],"name":{"displayForm":["Marie Luise Hütter-Krönke, Walter Fiedler, Andrea Kündgen, Jürgen Krauter, Marie von Lilienfeld-Toal, Hartmut Döhner, Richard F. Schlenk"]},"person":[{"given":"Marie-Luise","display":"Hütter-Krönke, Marie-Luise","role":"aut","family":"Hütter-Krönke"},{"given":"Richard Friedrich","display":"Schlenk, Richard Friedrich","role":"aut","family":"Schlenk"}],"recId":"1588230805","note":["Gesehen am 28.02.2019"]} | ||
| SRT | |a HUETTERKROCONTINUOUS2019 | ||